Johnson & Johnson (J&J; NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of an indication extension for TALVEY (talquetamab) – for use in combination with daratumumab, with or without pomalidomide, in adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy. The positive opinion positions the CD3 × GPRC5D bispecific antibody for a significantly earlier treatment setting than its current monotherapy label, pending a final European Commission (EC) decision.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Medicines Agency (EMA) – CHMP |
| Action | Positive opinion recommending approval of an indication extension |
| Product | TALVEY (talquetamab) |
| Company | Johnson & Johnson (NYSE: JNJ) |
| Proposed Regimen | Talquetamab in combination with daratumumab, with or without pomalidomide |
| Proposed Population | Adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy |
| Opinion Date | 16 Oct 2026 |
| Next Steps | Final decision by the European Commission (EC); timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Talquetamab – a bispecific antibody developed by J&J.
- Dual Targets: CD3 (T‑cell engager arm) and GPRC5D (myeloma cell surface antigen) – the bispecific design physically bridges patient T cells to GPRC5D‑expressing myeloma cells, driving immune‑mediated tumor killing independently of MHC presentation.
- Combination Strategy: The proposed extension pairs talquetamab with daratumumab, J&J’s anti‑CD38 monoclonal antibody backbone in myeloma, with or without pomalidomide, an immunomodulatory agent – combining two distinct mechanisms with established RRMM activity.
- Administration: Subcutaneous T‑cell‑redirecting therapy (dosing details for the combination regimen not disclosed in the announcement).
Regulatory History – From Fourth‑Line Monotherapy to Earlier‑Line Combination
| Date | Region | Authorization | Population |
|---|---|---|---|
| Aug 2023 | European Union | Conditional marketing authorisation (CMA) from the EC – monotherapy | Adult RRMM after ≥ 3 prior therapies (immunomodulatory agent, proteasome inhibitor, anti‑CD38 antibody), with progression on last therapy |
| Aug 2023 | United States | FDA approval – monotherapy | Adult RRMM after ≥ 4 prior lines (proteasome inhibitor, immunomodulatory agent, anti‑CD38 antibody) |
| Oct 2026 | European Union | CHMP positive opinion – indication extension, combination with daratumumab ± pomalidomide | Adult RRMM after ≥ 1 prior therapy |
The trajectory shows a deliberate line‑of‑therapy advance: from a heavily pretreated, triple‑class‑exposed monotherapy niche to a combination regimen as early as second line – materially expanding the eligible European patient population should the EC adopt the CHMP opinion.
Clinical Evidence – Combination Data
The CHMP recommendation follows clinical evaluation of talquetamab in combination with daratumumab, with or without pomalidomide, in RRMM patients who have received at least one prior therapy. Specific efficacy and safety data supporting the opinion were not detailed in the announcement (Not disclosed).
Market Impact & Outlook
- Earlier‑Line Positioning: Approval in the ≥ 1 prior therapy setting would move TALVEY from a late‑line salvage option into the mainstream RRMM treatment sequence – where the anti‑CD38 backbone daratumumab already anchors standard of care.
- Bispecific Franchise Depth: The extension reinforces J&J’s leadership in myeloma bispecifics, complementing its anti‑CD38 and CAR‑T franchises with a GPRC5D‑directed T‑cell engager.
- European Conversion Watch: CHMP opinions are typically adopted by the European Commission within a short procedural window; the final EC decision will determine the label’s effective expansion (timeline not disclosed).
- U.S. Parallel Potential: Investors will watch for corresponding FDA filings to extend the U.S. talquetamab label into the same earlier‑line combination setting (none announced).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the recommended indication extension for TALVEY (talquetamab), the anticipated European Commission decision, and potential regulatory actions in other regions. Actual results may differ materially due to risks including the EC review process, clinical and safety outcomes in the combination setting, competitive dynamics in RRMM therapy, and pricing and reimbursement conditions. A CHMP positive opinion does not guarantee final marketing authorisation.-Fineline Info & Tech
